Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BiomX Inc.

Market Cap 5.58M 4.81M 4.43M 4.16M 7.81M 528M 7.89M 52.33M 20.39M 258M 20.94M 20.5M 895M P/E Ratio 2026 *
-0.09x
P/E Ratio 2027 * -0.09x
Enterprise Value 5.58M 4.81M 4.43M 4.16M 7.81M 528M 7.89M 52.33M 20.39M 258M 20.94M 20.5M 895M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
73.05%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week-19.30%
Current month-56.35%
1 month+3.48%
3 months-89.96%
6 months-64.52%
Current year-70.59%
1 week 0.52
Extreme 0.5165
0.74
1 month 0.36
Extreme 0.3608
1.89
Current year 0.36
Extreme 0.3608
8.5
1 year 0.36
Extreme 0.3608
14.71
3 years 0.36
Extreme 0.3608
162.45
5 years 0.36
Extreme 0.3608
1,117.2
10 years 0.36
Extreme 0.3608
2,261
Manager TitleAgeSince
Chief Executive Officer 54 2026-03-03
Director of Finance/CFO 58 2026-02-26
Investor Relations Contact - 2024-09-30
Director TitleAgeSince
Director/Board Member 47 2025-12-25
Director/Board Member 48 2026-02-12
Director/Board Member 43 2026-02-24
Date Insider Type Main position Quantity % Market Cap.
Mar. 15Conversion

Director

6,960,000 436.7700%
Mar. 10Conversion

Director

1,340,000 84.0908%
Jan. 12Other

Director

3,300,000 216.1610%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-19.30%-92.92%-99.15% 5.63M
-0.12%-0.18%-12.80%-12.90% 43.58B
-2.17%+4.70%+293.71%+535.99% 34.03B
+0.44%-3.80%+12.51%-17.06% 29.77B
-1.60%-1.58%-0.19%+31.82% 29.82B
-0.29%+2.65%+13.24%+21.04% 25.42B
+3.54%+8.43% - - 13.87B
-1.26%-1.11%+53.37%+108.10% 13.35B
-1.04%-3.48%+2.42%+1.98% 12.85B
-1.18%-2.00%+107.41%+78.18% 12.22B
Average -0.46%-1.59%+41.86%+72.00% 21.49B
Weighted average by Cap. -0.54%+1.22%+60.66%+104.83%

Financials

2026 *2027 *
Net sales - -
Net income -38.2M -32.92M -30.31M -28.46M -53.44M -3.61B -54M -358M -140M -1.77B -143M -140M -6.13B -45.1M -38.87M -35.79M -33.6M -63.09M -4.26B -63.76M -423M -165M -2.09B -169M -166M -7.24B
Net Debt - -
Logo BiomX Inc.
BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.
Employees
20
Date Price Change Volume
26-06-16 0.5500 $ -0.88% 446,046
26-06-15 0.5549 $ +3.49% 1,008,538
26-06-12 0.5362 $ -24.24% 13,054,173
26-06-11 0.7078 $ +10.63% 389,084
26-06-10 0.6398 $ -6.12% 254,313
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5500
Average target price
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PHGE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!